Amarin Corp Plc (AMRN)

[eightisenough]

HDG-Jelis is differentiated: "Although promising, the JELIS trial was limited by an open-label design, lack of placebo control, and geographic limitation to patients in Japan."

Stick to accounting as you said, you are just an accountant and have no idea of patent LAW.

8